Threshold Pharma Reports New Clinical Data on TH-302, Says One CR, Two Partial

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD ), today announced early data from the Phase 1 portion of an investigator-sponsored Phase 1/2 trial of its investigational hypoxia-targeted drug TH-302 in combination with Avastin(R) (bevacizumab) in patients with recurrent glioblastoma following bevacizumab failure (Study 4003). No dose-limiting toxicity has been reported to date at doses of TH-302 up